{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:18:39Z","timestamp":1783923519184,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tjpad.2026.100586","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:05:51Z","timestamp":1778007951000},"page":"100586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer\u2019s disease"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-896X","authenticated-orcid":false,"given":"R.","family":"S\u00e1nchez Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lle\u00f3 Bisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-7620","authenticated-orcid":false,"given":"A.","family":"Villarejo Galende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cuartero Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Escudero-Torrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-5402","authenticated-orcid":false,"given":"N.","family":"Bargallo Alabart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tjpad.2026.100586_bib0001","article-title":"Disease-modifying treatments and their future in Alzheimer\u2019s Disease management","volume":"16","author":"Smith","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nrl.2017.10.005","article-title":"Report by the Spanish Foundation of the Brain on the social impact of Alzheimer disease and other types of dementia","volume":"36","author":"Villarejo Galende","year":"2021","journal-title":"Neurologia (Engl Ed)"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-240684","article-title":"A framework for best practices and readiness in the advent of anti-amyloid therapy for early Alzheimer\u2019s disease in Asia","volume":"101","author":"Lee","year":"2024","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100586_bib0004","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s Disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.tjpad.2026.100586_bib0005","series-title":"Anti-Amyloid monoclonal antibodies for the treatment of alzheimer\u2019s disease","first-page":"5","author":"Cummings","year":"2024"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100586_bib0006","first-page":"2","article-title":"Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q."},{"key":"10.1016\/j.tjpad.2026.100586_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1590\/0004-282x-anp-2022-s117","article-title":"Are we ready to use anti-amyloid therapy in Alzheimer\u2019s disease?","volume":"80","author":"Brucki","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/13872877241284312","article-title":"Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology","volume":"102","author":"Matias-Guiu","year":"2024","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100586_bib0009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1017\/cjn.2023.270","article-title":"A model predicting healthcare capacity gaps for Alzheimer\u2019s disease modifying treatment in Canada","volume":"51","author":"Black","year":"2024","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.tjpad.2026.100586_bib0010","unstructured":"Mattke S., Ullrich A., Wang M. Implications of Alzheimer\u2019s treatment for organization and payment of medical practices in the EU-5 countries. 2020; Technical Report, USC Dornsife Center for Economic and Social Research."},{"key":"10.1016\/j.tjpad.2026.100586_bib0011","unstructured":"Fitch K., Bernstein S.J., Aguilar M.D., Burnand B., LaCalle J.R., Lazaro P., et al. The RAND\/UCLA Appropriateness Method User\u2019s Manual. RAND Corporation, Santa Monica, CA. 2001. Available at: https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html."},{"issue":"19","key":"10.1016\/j.tjpad.2026.100586_bib0013","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Antiamyloid monoclonal antibody therapy for Alzheimer Disease: emerging issues in neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100586_bib0014","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat Aging"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100586_bib0015","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer Disease as a clinical-biological construct-an International Working Group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100586_bib0016","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100586_bib0018","unstructured":"Manzano A., Fortea J., Villarejo A., S\u00e1nchez del Valle R. Gu\u00eda oficial de pr\u00e1ctica cl\u00ednica en demencias. Sociedad Espa\u00f1ola de Neurolog\u00eda, Madrid. 2018. Available at: https:\/\/www.sen.es\/pdf\/guias\/Guia_Demencias_2018.pdf."},{"issue":"6","key":"10.1016\/j.tjpad.2026.100586_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14333","article-title":"Alzheimer\u2019s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer\u2019s Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care","volume":"21","author":"Atri","year":"2025","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14335","article-title":"The Alzheimer\u2019s Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer\u2019s disease and related disorders (DETeCD-ADRD): validated clinical assessment instruments","volume":"21","author":"Atri","year":"2025","journal-title":"Alzheimer\u2019s Dement"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100586_bib0021","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.nrl.2024.08.002","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology","volume":"40","author":"Su\u00e1rez-Calvet","year":"2025","journal-title":"Neurologia (Engl Ed)"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100586_bib0022","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1590\/1980-57642021dn15-040005","article-title":"Cognitive screening instruments for dementia: comparing metrics of test limitation","volume":"15","author":"Larner","year":"2021","journal-title":"Dement Neuropsychol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100586_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298686","article-title":"The diagnostic accuracy of the Mini-Cog screening tool for the detection of cognitive impairment\u2014A systematic review and meta-analysis","volume":"19","author":"Abayomi","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2026.100586_bib0024","unstructured":"European Medicines Agency. Leqembi (lecanemab): EPAR \u2013 product information. European Medicines Agency, Amsterdam. 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/leqembi-epar-product-information_en.pdf."},{"key":"10.1016\/j.tjpad.2026.100586_bib0025","unstructured":"European Medicines Agency. Kisunla (donanemab): EPAR \u2013 product information. European Medicines Agency, Amsterdam. 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisunla-epar-product-information_en.pdf."},{"key":"10.1016\/j.tjpad.2026.100586_bib0026","unstructured":"Ministerio de Sanidad. Plan de Inversiones en Equipos de Alta Tecnolog\u00eda (INVEAT). Ministerio de Sanidad, Madrid. Available at: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/PlanINVEAT\/home.htm."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0027","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer\u2019s and Dementia"},{"key":"10.1016\/j.tjpad.2026.100586_bib0028","unstructured":"Consejo de Seguridad Nuclear. El CSN informa favorablemente la ampliaci\u00f3n del Almac\u00e9n Temporal Individualizado de Santa Mar\u00eda de Garo\u00f1a. Consejo de Seguridad Nuclear, Madrid. 2025. Available at: https:\/\/www.csn.es\/-\/el-csn-informa-favorablemente-la-ampliacion-del-almacen-temporal-individualizado-de-santa-maria-de-garona."},{"key":"10.1016\/j.tjpad.2026.100586_bib0029","unstructured":"Gobierno de Canarias. Sanidad invierte m\u00e1s de once millones de euros en la adquisici\u00f3n de un ciclotr\u00f3n y un laboratorio para el HUC. Gobierno de Canarias, Santa Cruz de Tenerife. 2025. Available at: https:\/\/www3.gobiernodecanarias.org\/noticias\/sanidad-invierte-mas-de-once-millones-de-euros-en-la-adquisicion-de-un-ciclotron-y-un-laboratorio-para-el-huc\/."},{"issue":"12","key":"10.1016\/j.tjpad.2026.100586_bib0030","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimer\u2019s Dement : J Alzheimer\u2019s Assoc"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0031","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1002\/alz.14337","article-title":"The Alzheimer\u2019s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer\u2019s Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care","volume":"21","author":"Dickerson","year":"2025","journal-title":"Alzheimer\u2019s Dement"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100586_bib0032","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"The journal of prevention of Alzheimer\u2019s disease"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100586_bib0033","doi-asserted-by":"crossref","first-page":"e14335","DOI":"10.1002\/alz.14335","article-title":"The Alzheimer\u2019s Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer\u2019s disease and related disorders (DETeCD-ADRD): validated clinical assessment instruments","volume":"21","author":"Atri","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.tjpad.2026.100586_bib0034","unstructured":"Food and Drug Administration. Leqembi (lecanemab-irmb) injection, for intravenous use: prescribing information. Food and Drug Administration, Silver Spring, MD. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf."},{"key":"10.1016\/j.tjpad.2026.100586_bib0035","unstructured":"Food and Drug Administration. Kisunla (donanemab-azbt) injection, for intravenous use: prescribing information. Food and Drug Administration, Silver Spring, MD. 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf."},{"key":"10.1016\/j.tjpad.2026.100586_bib0036","unstructured":"Medicines and Healthcare products Regulatory Agency. Kisunla (donanemab): summary of product characteristics. Medicines and Healthcare products Regulatory Agency, London. 2024. Available at: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/8432592ad73d70d10334fc5526b41ea2f59175bd."},{"key":"10.1016\/j.tjpad.2026.100586_bib0037","unstructured":"Medicines and Healthcare products Regulatory Agency. Leqembi (lecanemab): summary of product characteristics. Medicines and Healthcare products Regulatory Agency, London. 2024. Available at: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/6ed2db79b7202feb5a8edbecfa5c35bb434381e6."},{"key":"10.1016\/j.tjpad.2026.100586_bib0038","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related imaging abnormalities and \u03b2-Amyloid-Targeting antibodies: a systematic review","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100586_bib0039","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/acn3.52042","article-title":"Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy","author":"Vukmir","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100586_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100586_bib0041","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11604-025-01773-x","article-title":"Practical brain MRI guidelines for anti-a\u03b2 antibody treatment in early symptomatic Alzheimer\u2019s disease","volume":"43","author":"Kakeda","year":"2025","journal-title":"Jpn J Radiol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:04:02Z","timestamp":1783922642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072600110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S227458072600110X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100586","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100586"}}